Gdc-0134    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis2

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03237741
(ClinicalTrials.gov)
August 7, 201731/7/2017Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female ParticipantsA Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing PotentialAmyotrophic Lateral SclerosisDrug: Reference capsule GDC-0134;Drug: Prototype capsule GDC-0134;Drug: rabeprazoleGenentech, Inc.Quotient ClinicalCompleted30 Years65 YearsFemale24Phase 1United Kingdom
2NCT02655614
(ClinicalTrials.gov)
May 31, 20167/1/2016A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral SclerosisA Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: GDC-0134;Drug: Placebo;Drug: Rabeprazole;Drug: Midazolam;Drug: CaffeineGenentech, Inc.NULLCompleted18 YearsN/AAll54Phase 1United States;Canada;Netherlands